Medical network - on February 16, cardiovascular drugs, the drug retail market in one of the major slow disease drug category, in the first half of 2016, total sales rose 6.0%, 22 cities fell 0.3%, compared with the same trend in contrast to the previous two years. Statins performance most prominent, with more than ninety percent of the market power, and share gradually increase.
A steady rise in adjusting blood fat drug market
In complex economic situation at home and abroad and the increased competition market environment, under the influence of drug retail industry growth is transition from rapid growth to steady growth, but growth is slowing. Cardiovascular drugs, the drug retail market in one of the major slow disease drug category, in the first half of 2016, total sales rose 6.0%, 22 cities fell 0.3%, compared with the same trend in contrast to the previous two years. Angina, coronary heart disease (CHD) drug use is one of the biggest in the cardiovascular medicine subclasses, market share accounted for half, followed by cerebrovascular, cerebral thrombosis (stroke), market share of nearly a quarter, adjusting blood fat drug market share of 22.1% (figure 1).
While adjusting blood fat drug market share of the three is the lowest, but its growth rate has maintained a larger, rose 3.9% year-on-year in the first half of 2016, 2012-2016 in the first half of the semi-annual compound growth rate of 11.0%, adjusting blood fat drug use (figure 2) market share is gradually rise, the market expands fast, incremental market is considerable, suggest continued attention, to develop a larger market.
Statins was the most outstanding
Disease of heart head blood-vessel of long-term chronic disease, proprietary Chinese medicine treatment has a unique advantage in this aspect, 22 cities combined cardiovascular medicine, proprietary Chinese medicine with a 70% market share, is ahead and this mainly by cardiovascular medicine of the larger angina, coronary heart disease (CHD) drug use, and cerebrovascular resistance, resistance to cerebral thrombosis (stroke) or two subclasses, and the fastest growing in the heart cerebrovascular drugs regulating lipid drug use is dominated by chemical medicine.
According to different therapeutic effect, the blood fat is divided into: the main drug is given priority to with lower blood total cholesterol and low density lipoprotein of statins, such as atorvastatin and simvastatin and pravastatin, etc. Betty class is given priority to with lower triglycerides, such as fenofibrate and benzalkonium bei etc.; And other drugs such as niacin, polyene fatty acid. Among them, statins for more than ninety percent of the market power, and share gradually increase. (figure 3)
Statins structure and hydroxymethyl glutaric acid formyl coenzyme A (HMG CoA) similar, can inhibit the HMG - CoA to armour hydroxyl of valeric acid, reduce cholesterol synthesis blocked, low density lipoprotein cholesterol (hdl-c), can make blood total cholesterol by 25% to 35%, low density lipoprotein decreased by 30% to 40%, reducing blood fat levels. Has clinical medical evidence that statins in the prevention of coronary heart disease, stroke and the treatment of acute cerebral apoplexy has important clinical significance, and therefore are more widely in the clinical applications of statins.
Statins market is highly concentrated
CR4 statin market is 81.9%, CR8 89.9%, belong to high oligopolistic market. Data show that statins comes mainly from the growth of atorvastatin and easy cutting statin two varieties.
Represented by Pfizer's lipitor tablets of atorvastatin advantage brand, building a high barriers to market intervention, the market share as high as 50% (table 1). Lipitor is Pfizer's fist product, on December 17, 1996, the FDA approal, become the world's first sales of more than 2004 billions of dollars in medicine. In 2007, the United States, approved by FDA atorvastatin increased to reduce the risk of nonfatal myocardial infarction and reduce the risk of fatal and nonfatal stroke and reduce the risk of supracricoid laryngectomy with reconstruction of blood supply, to reduce the risk of being hospitalized for congestive heart failure, angina, risk reduction, and other five indications so as to consolidate its in hyperlipidemia drug market in the leading position, its remarkable curative effect and safety of lipitor rapid growth of market share. On June 28, 2011, expire lipitor patent protection in the United States, have also has many domestic enterprises to copy, market share has slipped in recent years, but the market position of the lipitor is hard to shake.
Rui shu laval statin varieties but market expanded rapidly in recent years, although the brand is not much, but in statin brand list have accounted for two seats. Crestor piece (IPR Pharmaceuticals, INC.) came in second, march piece precede (nanjing east yuan) was ranked fifth. Can be set in 2012 - the first half of 2016 sales of semi-annual compound growth rate is 38. %, march slice of the growth of the compound rate of growth has three digits, growing larger and nanjing zhengda of this piece, the weather is fine, though not in the top ten, but performance is still outstanding.
Statins not only through the role of the single lipid-lowering effect, also through stable plaques, inhibiting inflammatory reaction and improve endothelial function, inhibit platelet aggregation effect of garment to complete together. They are first-line drugs, prevention and control of dyslipidemia, has been widely used in China, the people of the role of statins in clinical common recognition. Predictable, medicine retail market in China, statins as mature varieties in adjusting blood fat drug market, the future will continue to take over adjusting blood fat drug market in China.
(note: this article is based on the CFDA punctuation medical information institute of medicine economic south guangzhou co., LTD. Chinese medicine retail data monitoring and analysis system of 22 cities, for the first half of 2016 the brief analysis of cardiovascular drug retail market situation do. Contains 22 cities: Beijing, chengdu, guangzhou, Harbin, hangzhou, nanchang, nanjing, ningbo, Qingdao, Shanghai, shenzhen, suzhou, wuxi, wuhan, shenyang, shijiazhuang, changchun, changsha, zhengzhou, xi 'an, yangzhou, chongqing. In this paper, cardiovascular medicine means for anti angina, coronary heart disease, cerebrovascular, cerebral thrombosis (stroke), and regulating blood fat chemical medicines and proprietary Chinese medicine) |
